


European Platform for Regulatory science research

A mechanism for dialogue and collaboration between academic, public and non-for-profit regulatory science researchers and regulators

- To systematically **advance and accelerate research** addressing regulatory needs
- To refine and enrich regulatory topics with **research interests** and **methods expertise**
- To progress methodological standards and to increase the **quality and relevance** of research outputs for regulatory implementation
- To accelerate **translation of outputs** into improved R&D and regulatory practices
- To support **growth of academic researcher community** engaging on regulatory issues

Need for generating evidence...

...on a particular medicine under investigation



**Medicinal product
research, develop-
ment and evaluation**

...on methods and their application in developments

Domain I:
Investigating and
establishing tools and
methods for specific
activities in drug
development


Domain II:
Investigating and
establishing approaches
for optimising evidence
generation

Domain III:
Investigating and
evolving the regulatory
activities and system


**R&D of regulatory
science**

- **Pre-competitive**
- **Product-independent**
- Open science approach
- Often academia leading
- Often multiple stakeholders
- Often publicly financed


A systematic and strategic approach to advancing regulatory science




4



A structured discussion approach



Platform working model



Expansion of Platform's Steering Group

Adam Hacker (CEPI) (Co-chair)

Ronette Gehring (UU)

Madeline Pe (EORTC)

Marjon Pasmooij (MEB, Co-chair)

Kit Roes (MEB, Methodology WP)

Günter Waxenecker (AGES)

Ralf Herold (EMA, Co-chair)

Liese Barbier (EMA, Lead)

Ivana Silva (EMA)

Frank Pétavy (EMA)

Steffen Thirstrup (EMA)

Anja Minheere (EFNA)

Alexander Mathioudakis (HCPWP, ERS)


Nick Sykes (EFPIA)





The Platform's growing community

Over 300 researchers and scientists and counting



Pharmacometrics Regulatory – academic
Platform trials Regulatory sandbox collaboration
Funding opportunities Medical devices
Digital technologies Modelling
Patient experience data ATMPs Rare diseases
Real world data Accelerated pathways
Clinical trial methodology New approach methodologies
Nanomedicines Academic drug development
Regulatory – HTA interface AI & machine learning
Uncertainty communication Drug repurposing
Pharmacovigilance Benefit risk methodologies
Antimicrobial resistance Vaccines
Data availability and sharing ...
Biomarker validation



Platform meetings 2026



30 April 2026

13 – 17:00 CEST , online



16 June 2026

14 – 18:00 CEST, online



22 October 2026

10 – 17:00 CEST, hybrid



Platform meeting discussion topics 2026



30 April 2026

13 – 17:00 CEST , online

- Clinical trial registers and researcher use
- Research and evidence generation for medicines incl new uses
- HMA/EMA RWD catalogues



16 June 2026

14 – 18:00 CEST, online

- Research for AI regulatory science research needs
- Advancing research for new approach methodologies
- Achieving regulatory impact for your research project



22 October 2026

10:00 – 17:00 CEST, hybrid

- To be announced later

Platform meeting discussion topics 2026



30 April 2026

13 – 17:00 CEST , online



16 June 2026

14 – 18:00 CEST, online



22 October 2026

10:00 – 17:00 CEST, hybrid

[EMA's Regulatory Science Research Needs](#)

+


Suggestions by platform participants

+

Prioritisation by platform steering group


EPAR best-practice guide drafting group

Starting point: [Platform meeting May 2025](#), session *Use of regulatory data in research: spotlight on the EPAR*



Best-practice guide drafting group

- What is an EPAR
- Use and value of using EPARs in research
- Methodological approaches
- Other types of regulatory documents and data



Research project

- Scoping literature review
- Survey on experiences of first authors

Alessandro Lazdins, Odidison Philbeth, Marieke De Bruin, Malgorzata Kujawska, Christine Hallgreen, Ronette Gehring, Lourens Bloem, Caridad Pontes Garcia, Chera Kurdi, Andreas Kouroumalis, Carmen María González Domenech, John Liddicoat, Maribel Rico Salas, Maria Dul, Diogo Almeida, Maria Teixeira, Amanda Klein, Weam Fageera, Radu Popescu, Frank Petavy, Madeline Pe, Lucina Nollen, Elena Guillen, Fabio Borges, Liese Barbier, Marjon Pasmooij

Agenda for today

13:00 – 13:20 Welcome and introduction

13:20 – 14:20 Clinical trial registers and research use (60 min)

14:20 – 15:40 Research and evidence generation for medicines including new uses (80 min)

15:40 – 15:50 *Break*

15:50 – 16:50 HMA-EMA Catalogues of RWD sources and studies and use by researchers (60 min)

16:50 – 17:00 Meeting close